June 11, 2019 - Minneapolis, MN - Leading pharmacogenomics company OneOme today announced the launch of OneOme Institute, its new educational venture. OneOme Institute was developed to help advance the use of PGx in clinical practice worldwide.
Pharmacogenomics (PGx) is a rapidly advancing branch of precision medicine, backed by significant clinical and scientific evidence. Through PGx testing, healthcare providers can gain insight into how a patient’s DNA may affect the way certain medications work for them. This gives providers an important tool to help them in making prescribing decisions.
“As we work with partners around the globe, we’ve found that one of the barriers to adoption is that providers need more and better knowledge about PGx,” said Bernard Esquivel, MD, a practicing physician and medical director at OneOme and one of the key team members involved in OneOme Institute. “Through OneOme Institute, I hope to help increase their awareness about the benefits and limitations of PGx and help them incorporate PGx into their patients’ care.”
OneOme Institute will help provide foundational knowledge about PGx, its clinical utility, and OneOme’s RightMed PGx test through training courses and PGxperience events. OneOme Institute will also facilitate a collaboration network, which will bring together PGx experts including physicians, pharmacists, researchers, and other healthcare providers. This network is intended to support furthering PGx research, identifying and sharing clinical best practices for PGx, and providing opportunities for healthcare professionals interested in PGx to learn from acknowledged experts.
The initial training course, Getting started with pharmacogenomics, is set to be released later this summer, and OneOme Institute’s first PGxperience event is planned for August, 2019.
OneOme was co-founded with Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic.